false
OasisLMS
zh-CN,zh-TW,en,fr,de,hi,ja,ko,pt,es
Catalog
Using Teriparatide: Combination and Sequential The ...
Recording: Using Teriparatide: Combination and Seq ...
Recording: Using Teriparatide: Combination and Sequential Therapies
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Amal Shibli Rahal, an endocrinologist at the University of Iowa, led a webinar on the use of teriparatide in combination and sequential therapies for bone health. The focus was on the coupling of bone formation and resorption and the effects of administering teriparatide with anti-resorptive agents such as bisphosphonates and denosumab.<br /><br />She discussed the outcomes of using teriparatide alongside bisphosphonates, highlighting that combination therapies often do not provide significant advantages over teriparatide alone in treatment-naive patients. However, layering bisphosphonates after teriparatide might improve outcomes by reopening the anabolic window. Switching from long-term bisphosphonates to teriparatide still yields benefits, although with slightly diminished results compared to treatment-naive cases.<br /><br />For denosumab, combining it with teriparatide can be more effective than using either drug alone, though switching from denosumab to teriparatide may lead to initial bone density loss, making this sequence less favorable. After completing teriparatide treatment, transitioning to an anti-resorptive like bisphosphonates or denosumab is crucial to maintain the gains in bone density.<br /><br />The webinar also covered recent studies on transitioning between teriparatide and romosozumab, indicating that romosozumab may retain efficacy after prior teriparatide treatment, while the effect of teriparatide following romosozumab is less certain.<br /><br />The session concluded with considerations for patient-specific treatment strategies and questions regarding the clinical applications of these therapies, emphasizing the need for a tailored approach in managing osteoporosis and bone health. Dr. Rahal also addressed audience questions about duration and switching protocols for osteoporosis treatment.
Keywords
teriparatide
bone health
endocrinologist
bisphosphonates
denosumab
romosozumab
osteoporosis
combination therapy
anabolic window
bone density
×